TRANSVAC is a collaborative infrastructure project funded by the European Commission (EC), initially under the 7th Framework Programme (FP7) and currently under Horizon 2020.  The project is a joint effort of leading European groups working in the field of vaccine development, and is coordinated by the European Vaccine Initiative (EVI). TRANSVAC is designed to accelerate vaccine development by enhancing European vaccine research and training, and increase sustainability of EC vaccine projects by implementing a permanent research infrastructure for early vaccine development.

 OPEN CALL  

Apply for Vaccine Development Services and Training Now!

services at all stages

of the Vaccine R&D Pipeline                 

Free technical & theoretical courses at leading European centres               

Apply Now >>

Researchers developing vaccine candidates against #COVID19 are encourage to apply and benefit from all TRANSVAC2 services, such as:
 

   Adjuvant formulation - Vaccine Formulation Institute and Helmholtz Centre for Infection Research 
   Structural Biology - INSTRUCT

   Animal models - CEA, BPRC, IRTA-CReSA  and Helmholtz Centre for Infection Research 
   Clinical Trial Support - ECRIN (European Clinical Research Infrastructure Network)
   Regulatory support - EATRIS and European Vaccine Initiative

Check out all services available here >>>>

For specific inquiries on the details of each service please contact directly service providers

    Consider this

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N° 730964.